The American Medical Association quietly admits that hydroxychloroquine Azithromycin and vitamin D actually works as a treatment for Covid 19.
Trump was 100% RIGHT.
Whereas, The third hyperinflammatory phase (Stage 3), occurs when a hyperactivated immune
system may cause injury to the heart, kidneys, and other organs. A "cytokine storm"--where the
body attacks its own tissues--may occur in this phase; and
5 Whereas, There is no current Federal Drug Administration (FDA) indication for the treatment of
6 Early Coronavirus infection, but early emergency use authorization (EUA) originally approved
87 the use of hydroxychloroquine and then rescinded it (2); and
9 Whereas, The FDA limited use of convalescence plasma but now has rescinded that
10 limitation (3); and
11
12 Whereas, Hydroxychloroquine and Chloroquine are FDA approved medications for over
13 50 years, and these medications are safely prescribed long-term for other indications (2); and
14
15 Whereas, AMA President, Patrice A. Harris, MD, issued the following statement: “The AMA
16 is calling for a stop to any inappropriate prescribing and ordering of medications, including
17 chloroquine or hydroxychloroquine, and appealing to physicians and all health care
18 professionals to follow the highest standards of professionalism and ethics” (4); and
19
20 Whereas, The AMA, American Pharmacists Association, and American Society of Health
21 System Pharmacists issued a joint statement on March 25, 2020 on inappropriate ordering,
22 prescribing, or dispensing of medications to treat COVID-19 (4); and
23
24 Whereas, Some states, pharmacy boards and institutions have forbidden the use of these
25 medications for COVID-19 infection (4, 5); and
26
27 Whereas, A proposed regimen to treat COVID-19 for Stage 1, includes 10 days of
28 hydroxychloroquine, Azithromycin, zinc, and on occasion Vitamin D (6); and
29
30 Whereas, This regimen is not being advocated for Stage 2 and Stage 3 COVID therapy; and 31
32 Whereas, The original studies published in
33
34
35 (7, 8, 9); and
36
37 Whereas, AMA policy H-120.988, “Patient Access to Treatments Prescribed by Their
38 Physicians,” supports a physician’s autonomy to prescribe medications the physician believes to
39 be in the patient’s best interest, where the benefits outweigh risk and the patient consents; and
40
41 Whereas, Physicians have used off label medications for years and this use is supported by
42 existing policy; and
43
44 Whereas, Data regarding harm have been limited due to poorly designed studies or studies
45 usually in Stage 2 or later, or stopped without harm but no effect in phase 2 and hypothesis
46 (7, 8, 9, 10, 11, 12); and
47
48 Whereas, There are many studies that indicate that the use of Hydroxychloroquine,
49 Azithromycin is effective and front-line physicians are using the therapy where permissible
50 (13, 14, 15); and
Resolution: 509 (November 2020) Page 2 of 6
The Lancet and The New England Journal of
Medicine (NEJM) initially citing harm due to hydroxychloroquine and chloroquine use were
retracted by said journals due to dubious research methodology and incorrect conclusions
Resolution: 509 (November 2020) Page 3 of 6
1 Whereas, The COVID-19 pandemic is a serious medical issue, people are dying, and 32 physicians must be able to perform as sagacious prescribers; therefore be it
4 RESOLVED, That our American Medical Association rescind its statement calling for physicians
5 to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes
6 available to conclusively illustrate that the harm associated with use outweighs benefit early in
7 the disease course. Implying that such treatment is inappropriate contradicts AMA Policy
8 H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,” that addresses off
9 label prescriptions as appropriate in the judgement of the prescribing physician (Directive to
10 Take Action); and be it further
11
12 RESOLVED, That our AMA rescind its joint statement with the American Pharmacists
13 Association and American Society of Health System Pharmacists, and update it with a joint
14 statement notifying patients that further studies are ongoing to clarify any potential benefit of
15 hydroxychloroquine and combination therapies for the treatment of COVID-19 (Directive to Take
16 Action); and be it further
17
18 RESOLVED, That our AMA reassure the patients whose physicians are prescribing
19 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by
20 issuing an updated statement clarifying our support for a physician’s ability to prescribe an FDA-
21 approved medication for off label use, if it is in her/his best clinical judgement, with specific
22 reference to the use of hydroxychloroquine and combination therapies for the treatment of the
23 earliest stage of COVID-19 (Directive to Take Action); and be it further
24
25 RESOLVED, That our AMA take the actions necessary to require local pharmacies to fill valid
26 prescriptions that are issued by physicians and consistent with AMA principles articulated in
27 AMA Policy H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,”
28 including working with the American Pharmacists Association and American Society of Health
29 System Pharmacists. (Directive to Take Action)
